Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Success For Sanofi And Rouse

12/06/2021 | 01:15am EST

Well known life sciences company, Sanofi and it's Chinese brand name '赛诺菲' are highly regarded in the Chinese market. Unfortunately, these brands have been the targets of misuse across a wide range of industries including fraudulent examples such as 'Sanofi Environmental Protection Technology' and 'Sanofi Biotechnology'.

Sanofi has been successfully undertaking numerous actions against such uses including a recent landmark win. Sanofi began trade mark invalidation proceedings for the "Sanofi 赛诺菲" trade mark which was approved and registered on Class 11 Air purification devices and machines.

The Beijing Intellectual Property Court held that after long-term, widely publicised usage the "Sanofi" and "赛诺菲" trade marks are constituted as well-known trade marks. The owner of the disputed trade mark improperly took advantage of Sanofi's widely known brand, and the disputed trade mark was successfully declared invalid. This case was a success for Sanofi's future brand protection and will be a great reference when dealing with similar infringement cases in the future.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Ms Sharon Qiao
Rouse
4th Floor, City Tower
40 Basinghall Street
London
EC2V 5DE
UK
Tel: 207536 4100
Fax: 845 280 0201
URL: www.rouse.com

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about SANOFI
11:07aLiberum Reinstates Sanofi With Buy Rating
MT
01/24SANOFI : Second positive Phase 3 Dupixent« (dupilumab) trial confirms significant improvem..
PU
01/21SANOFI : Early redemption / Cancellation / Delisting
PU
01/20Exclusive-Polish drug maker Polpharma working on bid for Advent's Zentiva - sources
RE
01/19Regeneron Says FDA to Review Libtayo/Chemotherapy Combo in First-Line NSCLC Treatment
DJ
01/19Sanofi, Regeneron Say Dupixent Significantly Reduces Itching in Prurigo Nodularis Patie..
MT
01/19Sanofi-Regeneron's Dermatitis Drug Lowers Itch, Skin Lesions In Late-Stage Trial
MT
01/19Sanofi Announces Second Positive Phase 3 Dupixent« Trial Confirms Significant Improveme..
CI
01/17Factbox-GSK's consumer healthcare business coveted by Unilever
RE
01/15Factbox-GSK's consumer health business
RE
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2021 37 786 M 42 691 M 42 691 M
Net income 2021 6 139 M 6 936 M 6 936 M
Net Debt 2021 9 925 M 11 213 M 11 213 M
P/E ratio 2021 18,6x
Yield 2021 3,66%
Capitalization 113 B 128 B 128 B
EV / Sales 2021 3,26x
EV / Sales 2022 2,99x
Nbr of Employees 99 412
Free-Float -
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 90,25 €
Average target price 107,27 €
Spread / Average Target 18,9%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI-0.07%125 716
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963